James Singleton

James is General Counsel of Numab and Secretary of the Numab Board of Directors. Prior to joining Numab in October 2021, James served as General Counsel for Waypoint Capital (US) and its healthcare fund Gurnet Point Capital from 2016 to 2021, and also served on the board of Boston Pharmaceuticals, Tremeau Pharmaceuticals and Auregen BioTherapeutics Inc. From 2004 to 2016, James held senior legal leadership positions at Serono International SA and, following Merck’s acquisition of Serono, Merck KGaA, serving as Head of Legal for Serono Research & Development, Merck’s corporate venture fund Merck Ventures, Merck Biopharma Global Business Development and Merck Biosimilars.

James has over twenty years’ experience in the biopharmaceutical industry in the United States and Europe.

James received his Juris Doctor degree from NYU School of Law and his Bachelor of Arts degree from State University of New York at Albany.